Across the world, scientists are still trying to answer one of medicine’s most difficult questions: how can we safely and effectively treat brain cancers such as glioma? Despite decades of effort, outcomes for people diagnosed with high-grade glioma remain bleak. Current treatments, including surgery, radiotherapy, and chemotherapy, can slow the disease, but rarely stop it. The GlioLighT consortium, a multidisciplinary European research team funded by the European Innovation Council, has come together to explore a novel approach based on direct light therapy. Being in a very early stage, the project doesn’t promise an immediate cure; instead, it sets out to answer a very fundamental question: can light itself trigger biological processes that might form the basis of a safe and targeted brain tumor therapy?

For centuries, malaria has been one of the deadliest diseases on the planet. Nearly half of the world remains at risk of malaria with more than half a million deaths each year, most of them in children. While some progress has been made in controlling malaria and developing a vaccine, this has stalled recently, with a growing number of deaths since 2019. At the heart of the challenge is the lack of non-invasive and rapid diagnostic technologies for malaria, which are urgently needed, especially in remote or low-resource areas with limited healthcare infrastructure. Happily, a new frontier in medical technology is offering hope, in the form of the Cytophone, a revolutionary device that can detect malaria through the skin without drawing a single drop of blood. This innovation, developed by a team led by Prof. Vladimir Zharov at the University of Arkansas for Medical Sciences and licensed to Cytoastra for further commercialization, represents a leap forward not just in malaria diagnostics, but in how we might monitor disease altogether.